SSR 125543

Drug Profile

SSR 125543

Alternative Names: SSR 125543A; SSR-125543

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Antidepressants; Anxiolytics; Halogenated hydrocarbons; Thiazines
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Major depressive disorder; Post-traumatic stress disorders

Most Recent Events

  • 28 Apr 2011 Discontinued - Phase-II for Major depressive disorder in Belgium (PO)
  • 28 Apr 2011 Discontinued - Phase-II for Major depressive disorder in Canada (PO)
  • 28 Apr 2011 Discontinued - Phase-II for Major depressive disorder in Chile (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top